This is another IMPORTANT survey for Canadians with MS. Make your voice is heard, to ensure those conducting this survey understand how critical our DMDs are to maintaining our health and functioning.
Every provincial and territorial government in Canada has programs in place to provide Canadians with MS access to DMDs, in keeping with the spirit and intent of the Canada Health Act. Please provide your input to help ensure we retain funding for access to these important medications.
Frankly I'm cynical and distrustful of PM Harper and the PCs, particularly in light of the recent omnibus bill (C-45), and this government commissioned survey makes me rather nervous......
Survey on the Impact of MS Disease-Modifying Therapies
In late February, the Multiple Sclerosis Society of Canada will provide input on behalf of people with MS in regards to a review of the current and emerging disease-modifying therapies (DMT's) for MS taking place by the national agency that makes recommendations to provincial and territorial drug program decision makers.
The national agency - Canadian Agency for Drugs and Technologies in Health (CADTH) is currently undertaking a systematic review to compare the efficacy and safety of DMT's for patients with relapsing-remitting MS and will examine their cost-effectiveness.
The review will include DMT's that are currently available in Canada (Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, and Tysabri) and newly emerging DMT's not yet approved in Canada (teriflunomide, dimethyl fumarate (BG-12), and alemtuzumab).
To ensure the views of Canadians affected by MS are truly represented, we are asking people with MS as well as caregivers to complete the following survey. Your answers will be incorporated into the submission to the national agency - CADTH.
Please complete the survey by Friday, March 1.
http://mssociety.ca/en/involved/advocacy/default.htm#survey